"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
HIV Infection

About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV, AIDS, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: HIV patients > 18 years old who provide signed and dated Informed consent. HIV patients who have been receiving lopinavir/ritonavir and two nucleosides during at least 4 weeks. Plasma HIV RNA < 50 cop/ml for six months Exclusion Criteria: HIV patients who have stopped a protease inhibitor due to virological failure. HIV patients with hepatic or renal insufficiency. HIV patients with positive serum HBVAg HIV patients who require treatment with a lopinavir/r contraindicated medication. HIV pregnant or breastfeeding women. Active drug abuse (including alcohol or recreational drugs). Exception, cannabis, provided the investigator is confident in patient adherence. Patients under Methadone program will be accepted too if deemed appropriate by the investigator.
Sites / Locations
- Hospital General de Elche
- Hospital de Bellvitge
- Hospital Insular
- Hospital de Donostia
- Hospital U. Príncipe de Asturias
- Hospital Xeral Cies
- Hospital Universitario de Canarias
- Hospital de Basurto
- Hospital General de Alicante
- Hospital del Mar
- Hospital Sant Creu i Sant Pau
- Hospital Clinic i Provincial
- Hospital Germans Trias i Pujol
- Hospital Virgen de las Nieves
- Hospital La Paz
- Hospital La Princesa
- Hospital Gregorio Marañón
- Hospital Ramón y Cajal
- Fundación Jiménez Díaz
- Hospital Clínico San Carlos
- Hospital 12 de Octubre
- Hospital Virgen Macarena
- Hospital Nuestra Señora de Valme (Sevilla)
- Hospital La Fe
- Hospital Clínico de Valencia
- Hospital General de Valencia
- Hospital Dr. Peset
- Hospital Miguel Servet